Bumper Listing: Kronox Lab Sciences Makes Strong Debut On Exchanges, 21% Premium From IPO Price

Kronox Lab Sciences made a strong debut on Dalal Street on Monday, listing at Rs 164.95 on the National Stock Exchange (NSE) and Rs 165 on the Bombay Stock Exchange (BSE). This marked a premium of 21.29% and 21.32% respectively over its issue price of Rs 136 per share, reflecting robust investor interest in the pharmaceutical sector.

The listing performance was in line with expectations, as indicated by the strong grey market premium for the company. Prior to its listing, Kronox Lab Sciences shares commanded a grey market premium of Rs 28 per share, signalling anticipated listing gains of around 21% for investors.

The company's initial public offering (IPO), which was open for subscription from June 3 to June 5, saw overwhelming demand from investors. The IPO, priced in the range of Rs 129 to Rs 136 per share with a lot size of 110 shares, garnered significant attention from both institutional and retail investors.

Subscription figures for the IPO were impressive, with the offering oversubscribed by 118.22 times at close. Institutional investors showed strong interest, with the qualified institutional bidders (QIBs) segment oversubscribed 89.03 times. Non-institutional investors flocked to the IPO, driving the segment to be oversubscribed by 302.99 times. Even retail investors participated enthusiastically, with the retail segment witnessing a subscription of 55.72 times.

Analysts at various brokerage firms expressed optimism about Kronox Lab Sciences' IPO, citing its sound fundamentals, strong market positioning, and robust customer relationships worldwide. The company's ability to capitalize on growth opportunities, coupled with its solid moats, attracted positive sentiment from market experts.

"Kronox Lab Sciences, a prominent player in the specialty fine chemicals sector, witnessed a decent listing on the stock exchanges. The company debuted at Rs. 165 per share, translating to a 21% gain over its issue price of Rs. 136. While this marks a positive performance, it falls short of pre-listing expectations fueled by the initially high grey market premium (GMP) that had declined steadily in the days leading up to the listing. The company enjoys a strong position within the specialty fine chemicals sector, with a diverse product portfolio and competitive advantages due to high entry and exit barriers," said Shivani Nyati, Head of Wealth, Swastika Investmart Ltd.

"The current market volatility might have contributed to a more tempered listing performance compared to expectations. Kronox Lab Sciences' listing, while not quite reaching the heights anticipated based on the initial GMP, signifies a decent debut with strong investor interest. However, the lower-than-expected premium and ongoing market volatility highlight the need for a cautious approach. Investors are suggested to hold their position with a stop-loss level of 150," Nyati added further.

Ahead of the IPO opening, Kronox Lab Sciences raised approximately Rs 39 crore from anchor investors, indicating strong institutional support for the offering. Notable participants in the anchor round included Negen Undiscovered Value Fund, Chanakya Opportunities Fund I, Minerva Emerging Opportunities Fund, Capri Global Capital, Moneywise Financial Services, and VPK Global Ventures Fund.

The IPO, which raised a little over Rs 130 crore through the public issue, consisted entirely of an offer for sale (OFS) of up to 97.5 lakh shares. Shareholders Jogindersingh Jaswal, Ketan Ramani, and Pritesh Ramani, all part of the promoter group, divested their stakes through the offering. As a result, the IPO proceeds will go to the selling shareholders.

In terms of business overview, Kronox Lab Sciences specializes in manufacturing High Purity Specialty Fine Chemicals catering to various industries. Its products play crucial roles as reacting agents and raw materials in Active Pharmaceutical Ingredients (APIs) production, excipients in pharmaceutical formulations, and reagents for scientific research. Additionally, these chemicals find applications in nutraceuticals, biotech, agrochemicals, personal care products, metal refineries, and animal health products.

Revenue diversification is a key strength for Kronox Lab Sciences, with Pharmaceuticals contributing 45%, Scientific Research and Lab Testing 26%, Nutraceuticals 24%, and other sectors contributing 5% to its revenues.

The successful IPO and strong market debut reflect investor confidence in Kronox Lab Sciences' business model, growth prospects, and its potential to emerge as a key player in the specialty chemicals industry. As the company embarks on its journey as a publicly listed entity, all eyes will be on its performance and future expansion plans in the pharmaceutical space.